IdeZ protease does not prevent convertase stabilization by C3 nephritic factors in C3 glomerulopathy.
作者信息
Stevens Kes H, Baas Laura M, van de Kar Nicole C A J, van den Heuvel Lambertus P W J, Michels Marloes A H M
机构信息
Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Genetics, Translational Metabolic Laboratory, Radboud University Medical Center, Nijmegen, The Netherlands.
出版信息
Nephrol Dial Transplant. 2025 Aug 1;40(8):1628-1631. doi: 10.1093/ndt/gfaf065.
Abstract
摘要
相似文献
1
IdeZ protease does not prevent convertase stabilization by C3 nephritic factors in C3 glomerulopathy.
Nephrol Dial Transplant. 2025 Aug 1;40(8):1628-1631. doi: 10.1093/ndt/gfaf065.
2
Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Front Immunol. 2021 Aug 11;12:715704. doi: 10.3389/fimmu.2021.715704. eCollection 2021.
3
Analysis of C3 Nephritic Factors by ELISA.
Methods Mol Biol. 2019;1901:177-182. doi: 10.1007/978-1-4939-8949-2_13.
4
Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Front Immunol. 2019 Jun 17;10:1350. doi: 10.3389/fimmu.2019.01350. eCollection 2019.
5
Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.
Front Immunol. 2019 Apr 24;10:886. doi: 10.3389/fimmu.2019.00886. eCollection 2019.
6
C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Kidney Int. 2017 Nov;92(5):1232-1241. doi: 10.1016/j.kint.2017.04.017. Epub 2017 Jul 14.
7
C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Am J Kidney Dis. 2017 Dec;70(6):834-843. doi: 10.1053/j.ajkd.2017.07.004. Epub 2017 Aug 24.
8
Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Kidney Int. 2012 Nov;82(10):1084-92. doi: 10.1038/ki.2012.250. Epub 2012 Aug 1.
9
Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Front Immunol. 2018 Apr 4;9:612. doi: 10.3389/fimmu.2018.00612. eCollection 2018.
10
A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.
J Immunol. 2014 May 15;192(10):4844-51. doi: 10.4049/jimmunol.1303131. Epub 2014 Apr 11.
本文引用的文献
1
Complement inhibitors for kidney disease.
Nephrol Dial Transplant. 2023 Nov 8;38(Supplement_2):ii29-ii39. doi: 10.1093/ndt/gfad079.
2
Challenges in diagnostic testing of nephritic factors.
Front Immunol. 2022 Nov 14;13:1036136. doi: 10.3389/fimmu.2022.1036136. eCollection 2022.
3
Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in Severe Kidney Disease: An Open-Label Phase 2a Study.
J Am Soc Nephrol. 2022 Apr;33(4):829-838. doi: 10.1681/ASN.2021111460. Epub 2022 Mar 8.
4
Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation.
Am J Transplant. 2022 Mar;22(3):691-697. doi: 10.1111/ajt.16828. Epub 2021 Sep 13.
5
Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes).
Transplantation. 2021 Aug 1;105(8):1808-1817. doi: 10.1097/TP.0000000000003496.
6
Administration of immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) for persistent anti-ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission.
Br J Haematol. 2019 Jul;186(1):137-140. doi: 10.1111/bjh.15706. Epub 2018 Nov 29.
7
Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Front Immunol. 2018 Oct 15;9:2329. doi: 10.3389/fimmu.2018.02329. eCollection 2018.
8
Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.
Biomed Res Int. 2017;2017:2180508. doi: 10.1155/2017/2180508. Epub 2017 May 9.
9
Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Kidney Int. 2012 Nov;82(10):1084-92. doi: 10.1038/ki.2012.250. Epub 2012 Aug 1.
10
IdeS: a bacterial proteolytic enzyme with therapeutic potential.
PLoS One. 2008 Feb 27;3(2):e1692. doi: 10.1371/journal.pone.0001692.
Zotero 插件